Remedy Entertainment Oyj (HEL:REMEDY)

Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 193.53 million. The enterprise value is 182.40 million.

Market Cap	193.53M
Enterprise Value	182.40M

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	n/a

Share Statistics

HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.44% in one year.

Current Share Class	13.59M
Shares Outstanding	13.59M
Shares Change (YoY)	+0.44%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	33.87%
Owned by Institutions (%)	5.72%
Float	8.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.25
PB Ratio	3.42
P/TBV Ratio	3.96
P/FCF Ratio	n/a
P/OCF Ratio	42.88
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.00
EV / Sales	3.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.32.

Current Ratio	3.25
Quick Ratio	3.25
Debt / Equity	0.32
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.47

Financial Efficiency

Return on equity (ROE) is -20.83% and return on invested capital (ROIC) is -35.90%.

Return on Equity (ROE)	-20.83%
Return on Assets (ROA)	-9.94%
Return on Invested Capital (ROIC)	-35.90%
Return on Capital Employed (ROCE)	-20.15%
Weighted Average Cost of Capital (WACC)	9.10%
Revenue Per Employee	153,770
Profits Per Employee	-33,669
Employee Count	387
Asset Turnover	0.64
Inventory Turnover	n/a

Taxes

Income Tax	-2.67M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.71% in the last 52 weeks. The beta is 0.89, so HEL:REMEDY's price volatility has been lower than the market average.

Beta (5Y)	0.89
52-Week Price Change	+0.71%
50-Day Moving Average	15.27
200-Day Moving Average	15.04
Relative Strength Index (RSI)	39.50
Average Volume (20 Days)	6,084

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 59.51 million and -13.03 million in losses. Loss per share was -0.96.

Revenue	59.51M
Gross Profit	49.04M
Operating Income	-14.86M
Pretax Income	-15.70M
Net Income	-13.03M
EBITDA	-11.97M
EBIT	-14.86M
Loss Per Share	-0.96

Balance Sheet

The company has 29.40 million in cash and 18.27 million in debt, with a net cash position of 11.13 million or 0.82 per share.

Cash & Cash Equivalents	29.40M
Total Debt	18.27M
Net Cash	11.13M
Net Cash Per Share	0.82
Equity (Book Value)	56.59M
Book Value Per Share	4.16
Working Capital	31.00M

Cash Flow

Operating Cash Flow	4.51M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 82.40%, with operating and profit margins of -24.98% and -21.90%.

Gross Margin	82.40%
Operating Margin	-24.98%
Pretax Margin	-26.39%
Profit Margin	-21.90%
EBITDA Margin	-20.12%
EBIT Margin	-24.98%
FCF Margin	n/a

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.44%
Shareholder Yield	-0.44%
Earnings Yield	-6.73%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEL:REMEDY has an Altman Z-Score of 4.39 and a Piotroski F-Score of 5.

Altman Z-Score	4.39
Piotroski F-Score	5